Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.07464, expectations were $-0.17.
Stay updated with breaking news from Farzin Haque. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.07464, expectations were $-0.17.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
This biotech company could rally if its drug successfully treats autoimmune diseases affecting the kidneys.
Operator: Greetings. Welcome to Aurinia Pharmaceuticals Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Operator: Greetings. And welcome to Aurinia Pharmaceuticals Incorporated Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.